PSB-CB5

CAS No. 1627710-30-8

PSB-CB5( —— )

Catalog No. M34207 CAS No. 1627710-30-8

PSB-CB5 (GPR18-IN-32)2 is a GRP18 antagonist with anti-inflammatory activity and can be used to study obesity and metabolic disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 183 In Stock
10MG 310 In Stock
25MG 519 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PSB-CB5
  • Note
    Research use only, not for human use.
  • Brief Description
    PSB-CB5 (GPR18-IN-32)2 is a GRP18 antagonist with anti-inflammatory activity and can be used to study obesity and metabolic disorders.
  • Description
    PSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    GPR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1627710-30-8
  • Formula Weight
    384.88
  • Molecular Formula
    C20H17ClN2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C\1N2C(=N/C1=C\C3=CC(OCC4=CC=C(Cl)C=C4)=CC=C3)SCCC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kotańska M, et al. Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating. Pharmaceuticals (Basel). 2021;14(3):270.?
molnova catalog
related products
  • GW-1100

    GW-1100 is a selective GPR40 and FFAR1 antagonist for the study of diabetes and metabolic diseases.

  • Myristyl nicotinate

    Myristyl nicotinate is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer.

  • YE 120

    YE 120 is a highly potent GPR35 agonist (EC50: 32.5 nM) with potential anti-inflammatory and anti-cancer activities, which can be used to study G protein-coupled receptor-related diseases.